Objectives:
'Ib study the immunomodulatory effects of growth hormone (GH) and to investigate whether these effects are associated with the improvement of left ventricular (LV) contract& performance in dilated cardiomyopathy (DC) patients (pts).
Background: Recent studies indicate that an abnormal immune response contributes to the progression of chronic heart failure (CHF).
Methods:
Plasma inflammatory cyiokines TNFa. IL-6, GM-CSF, its soluble receptor sGM-CSFR and MCP-I, soluble adhesion molecules slCAM-1 and sVCAM-I, and antiinflammatory cytokines IL-10 and TGF-P were measured (EL&A) in 12 DC pts (NYHA III;
LVEF:24+3%) before and after a 3-month subcutaneous administration of GH 4lU every other day (randomized crossover design). Peak oxygen uptake (VO2 max). end-systolic wall stress (ESWS), mean velocity of circumferential fiber shortening (Vdc) and contractile reserve (change of VcfclESWS after dobutamine infusion) were also determined.
Resulte: GH produced a significant reduction in plasma TNFa (7.6kl.l vs 5.4kO.9 pg/ ml, pcO.Ol), IL-6 (5.6*0.5 vs 4X+0.3 pgiml, p<O.O5), GM-CSF (27*2 vs 23+2 pgiml, p<O.O5), sGM-CSFR (4.OkO.4 vs 3.210.3 ng/ml, ~~0.05). MCP-1 (199*5 vs 182*6 pg/ml, class improved from IV to I in Ppts, from IV to II in 2, and from IV to 11-111 in l.All pts were discharged from the hospitaLIt was possible to optimize long-term CHF treatment with up to 50 mg of carvedilol in 4 pts and higher doses of captopril(l50 mg) in all patients.Two pts are alive after 40 and 46 months of follow-up.The remaining 3 pts died from a pulmonary abscess at 9 months, septicemia at 21 months. and unplanned withdrawal of carvedilol at 36 months. Backgrounet Treatment wth Spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF). In the RALES-trial SPL was well tolerated, particularly with regard to renal function and serum-@ levels.
Aim: To investigate whether the reported low frequency of adverse effects during SPL treatment in a heart failure population could be confirmed in an unselected heart failure outpatient cohort
We investigated 125 consecutive patients with CHF recruited from our heart failure clinic. Inclusion criteria were LVEF ~45% and treatment with SPL. Mean age was 72.9 yrs (range 46.5-90.6), 27 4 % were women. NYHA-class distribution was: I: 5.7 %; II: 43.9 %; Ill: 46.3 % and IV. 4.1 %. Mean EF was 28 8 +/-4.5%. Other medications included ACE-I in 64.0% and betablockers in 32.6%. Blood tests were performed monthly or more frequently If necessary.
Results
At baselme creatinme levels were 117.4+X5 (mean+/-SD; mmolll, normal ~130) and serum-Q was 4.1+/-0.3 mmolll. The mean follow-up period was 11 months, and the cumulative observation period was 73 SPL treatment yrs. 60 pts. were already on SPL when admitted to the CHF clinic, with >30% receiving >25 mgld. The remainder were Initiated on SPL, with 9% receiving a dose >25 mg/d. During the follow-up period a total of 30.0% of the pts. developed hyperkalemia (>5 mmolll), wth 6.3% having serumKf >6 mmol/l. 53.3% of all patients had an increase of s-creatimne of z-20%, and 23.3% increased >50%. These alterations in s-creatinins and serum-@ were not significantly more frequent in patients treated with ACE-I or betablokkers or high-dose SPL (>I00 mg/ d). Aldosterone was measured at baseline and at least one post-baseline tlmepoint (4. 12,
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